Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | GRM8 | O00222 | 2/20 | 0.34 |
| ▸ | GRM6 | O15303 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634171 | 1.00 | LMNA (0.38) | LMNAHPGDHRH3KCNH2CYP2C19 | |
| SCHEMBL1634584 | 1.00 | LMNA (0.38) | LMNAHPGDHRH3KCNH2CYP2C19 | |
| SCHEMBL1634637 | 1.00 | LMNA (0.38) | LMNAHPGDHRH3KCNH2CYP2C19 | |
| SCHEMBL1635774 | 1.00 | LMNA (0.38) | LMNAHPGDHRH3KCNH2CYP2C19 | |
| SCHEMBL1634054 | 0.97 | LMNA (0.39) | LMNAHPGDHRH3KCNH2CYP2C19 | |
| SCHEMBL301094 | 0.92 | — | — | |
| SCHEMBL301224 | 0.87 | — | — | |
| SCHEMBL20985243 | 0.87 | — | — | |
| SCHEMBL20985252 | 0.87 | — | — | |
| SCHEMBL1635770 | 0.78 | HRH3 (0.36) | LMNAHPGDHRH3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932245-B2 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES (US) | 2011-04-26 | — | — | US | claimed |
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| EP-1558230-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | claimed |
| WO-2004037240-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-7932245-B2 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1558230-B1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| EP-1558230-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004037240-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | LMNA 1139/4885HPGD 593/4885HRH3 3106/4885 |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | LMNA 1606/4885HPGD 2262/4885HRH3 125/4885 |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | LMNA 1139/4885HPGD 593/4885HRH3 3106/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | LMNA 1150/4885HPGD 2066/4885HRH3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.